Home Sectors Healthcare Trading Results: IDEXX Laboratories (NASDAQ: IDXX)

Trading Results: IDEXX Laboratories (NASDAQ: IDXX)

9
0
SHARE

IDEXX Laboratories is in the medical diagnostics and research industry and is in the healthcare sector. The company CEO is Jonathan W. Ayers. IDEXX Laboratories Inc develops, manufactures and distributes products and provide services for companion animal veterinary, livestock and poultry, dairy and water testing markets.

Previous Intraday Trading Performance:

The IDXX stock showed a previous change of 0.45% with an open at 206.02 and a close of 207.74. It reached an intraday high of 207.90 and a low of 204.81.

SeekingAlpha:  IDEXX Laboratories, Inc. (IDXX) CEO Jonathan Ayers on Q4 2018 Results – Earnings Call Transcript

Liquidity:

The stock has a market cap of $17.9b with 86.2m shares outstanding, of which the float is 84.6m shares. Trading volume reached 371,950 shares compared to its average volume of 583,603 shares. Based on the current average volume and close price, the trading liquidity is good.

Historical Trading Performance:

Over the last five trading days, IDEXX Laboratories shares returned 2.25% and in the past 30 trading days it returned 10.53%. Over three months, it changed 1.88%. In one year it has changed 11.22% and within that year its 52-week high was 256.22 and its 52-week low was 172.37. IDXX stock is 20.52% above its 52 Week Low.

Our calculations show a 200 day moving average of 217.42 and a 50 day moving average of 196.21. Currently IDXX stock is trading -4.45% below its 200 day moving average and may be a good opportunity to buy, but should check other indicators to confirm a buy signal.

SeekingAlpha:  IDEXX Laboratories Q4 top line up 9%

Earnings:

The last annual fiscal EPS for the company was reported at 4.27 that ended on 31st of December 2018, which according to the previous close, that is a PE of 70.66. Based on 4 analyst estimates, the consensus EPS for the next quarter is 0.90. The TTM EPS is 4.27, which comes to a TTM PE of 48.65. Historically, the PE high was 70.90 and the PE low was 25.80. If the stock reached its PE low, that would represent a price of 110.17, which is a decrease of -46.97%.

The following are the last four quarter reported earnings per share:
12-31-2018:  0.98
09-30-2018:  1.05
06-30-2018:  1.23
03-31-2018:  1.01

Base on our calculations, the intrinsic value per share is 70.03, which means it may be overvalued by -196.66%

Indicators to Watch:

Based on the latest filings, there is 123.30% of institutional ownership. Short-interest is 0, which is 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio is 0.00.

The current calculated beta is 1.00

SeekingAlpha:  IDEXX Laboratories beats by $0.08, beats on revenue

Fundamental Indicators:

Based on last reported financials, the company’s return on assets is 23.73%, profit margin is 17.04%, price-to-sales is 8.06 and price-to-book is 196.21.

Company Scores:

All scores are out of six:
 0  :Valuation Score
 5  :Past Performance Score
 2  :Financial Strength Score
 2  :Future Growth Score
 0  :Dividend Score
 2  :Overall Score

SHARE
John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.